Please assess the completion status of the following clinical trial:

Trial Title: Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months.~* Has HbA1c of 7.1% to 11.0%, inclusive.~* Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.~Exclusion Criteria:~* Received any investigational drug within 3 months prior to screening.~* Is currently treated with any of the following excluded medications: \*Thiazolidinediones within 3 months of screening; \* Sulfonylureas within 3 months of screening; \* Insulin within 1 year of screening.~* Participated previously in an exenatide clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A1 (Type: PLACEBO_COMPARATOR): Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
- Group A2 (Type: PLACEBO_COMPARATOR): Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
- Group B (Type: EXPERIMENTAL): Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
- Group C (Type: EXPERIMENTAL): Exenatide lead-in followed by exenatide LAR 2.0 mg weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).